Carcinoma In Situ Of Ureter C4721448
An early-stage cancer confined to the inner lining of the ureter, the tube connecting kidney to bladder. Surgical removal of the affected tissue is the primary treatment.
Key facts at a glance
- ICD-10
- D01.2, D02.1, D07.61
- ICD-11
- 3A00.0
- Body system
- genitourinary
- Severity
- moderate
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(genitourinary)Noticeable symptoms that may vary in intensity over time.
Frequency: Varies
Gross hematuria
(genitourinary)Flank pain
(genitourinary)Urinary frequency
(genitourinary)Weight loss
(genitourinary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Ureteroscopy with laser ablation
Endoscopic laser treatment to destroy carcinoma in situ cells while preserving the ureter. A thin scope is inserted through the urethra and bladder into the ureter to visualize and ablate abnormal tissue.
Smoking cessation program
Structured smoking cessation support given the strong association between tobacco use and urothelial carcinoma. Smoking is a major risk factor for progression and recurrence.
Additional treatment options
Radical nephroureterectomy
Complete removal of the kidney, ureter, and surrounding tissue for extensive carcinoma in situ. This is a more invasive procedure reserved for disease that cannot be controlled with endoscopic approaches.
surgicalAdjuvant intravesical chemotherapy
Instillation of chemotherapeutic agents such as mitomycin C into the urinary tract to prevent recurrence of carcinoma in situ cells after endoscopic treatment.
procedureRegular surveillance cystoscopy
Periodic endoscopic examination of the urinary tract to detect recurrence of carcinoma in situ. Typically performed every 3-6 months initially, then extended if no recurrence.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Carcinoma In Situ Of Ureter C4721448?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Carcinoma In Situ Of Ureter C4721448. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy